Screening for Cervical Cancer with Human Papillomavirus (HPV) — NCD 365 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 365 governing HPV screening coverage, with a policy review date of January 9, 2026. Here's what billing teams need to know before submitting cervical cancer screening claims for Medicare beneficiaries.

CMS HPV screening coverage under NCD 365 Medicare has been in place since July 9, 2015 — but this review confirms the standing rules and clarifies the scope of what Medicare will and won't pay for. The policy does not list specific CPT or HCPCS codes, so your billing team needs to rely on the clinical criteria to determine whether a claim qualifies. If you bill HPV co-testing or standalone Pap services to Medicare, this policy directly governs your reimbursement.

Quick-Reference Table

CMS Cervical Cancer Screening Coverage Criteria and Medical Necessity Requirements 2026

The CMS cervical cancer screening coverage policy under NCD 365 covers HPV testing as an "additional preventive service" under §1861(ddd) of the Social Security Act. Coverage is not automatic. It requires meeting all four of these conditions simultaneously.

First, the patient must be asymptomatic. If the patient presents with symptoms, this is a diagnostic visit — not a preventive screen. That distinction changes the billing entirely. Diagnostic HPV testing falls outside this coverage policy.

Second, the patient must be between ages 30 and 65. Medicare does not cover HPV screening under this NCD for beneficiaries under 30 or over 65. The policy is explicit on this. There's no gray area here, and billing outside this age band is a fast path to claim denial.

Third, HPV testing must be performed in conjunction with a Pap smear test. Standalone HPV testing — without an accompanying Pap — is not covered under NCD 365. The two services are linked. Your billing team should treat them as a co-test bundle, not separate line items from a coverage standpoint.

Fourth, testing must occur no more than once every five years. This is the interval requirement that generates the most claim denial problems. Medicare tracks beneficiary-level utilization. If a claim comes in under the five-year mark, expect a denial. Build this frequency check into your pre-billing workflow.

The laboratory performing HPV testing must use FDA-approved or FDA-cleared tests. Tests must be used consistent with FDA-approved labeling. The lab must also comply with Clinical Laboratory Improvement Act (CLIA) regulations. These aren't just administrative boxes — non-compliant labs can lose Medicare billing rights entirely.

Whether HPV co-testing qualifies for reimbursement under this coverage policy comes down to those four criteria. Miss any one of them, and the claim doesn't qualify. Prior authorization is not listed as a requirement for this service under NCD 365, but meeting medical necessity criteria is still the billing team's burden to document.

CMS HPV Screening Exclusions and Non-Covered Indications

CMS is direct about what falls outside this coverage policy. Any preventive service not specifically covered by NCD 365, another applicable NCD, or by statute or regulation is non-covered by Medicare. That's not ambiguous — it's a closed list.

The most common billing error here involves symptomatic patients. If a patient has symptoms related to cervical or vaginal health, this visit is diagnostic, not preventive. Billing it under a preventive screen code is incorrect coding and a medical necessity problem.

Standalone HPV testing without a concurrent Pap smear is also non-covered under this NCD. Some labs bill HPV reflex testing or standalone HPV genotyping separately. Under NCD 365, that doesn't qualify. If the Pap wasn't performed at the same encounter, the HPV test doesn't meet coverage criteria here.

Finally, beneficiaries outside the 30–65 age window don't qualify. A 66-year-old asymptomatic patient with no prior abnormal results is not covered under this NCD. Neither is a 28-year-old. Medicare does cover a pelvic exam and Pap test separately — see 42 C.F.R. § 410.56 — but those services have their own intervals and rules. Don't conflate the two.

Coverage Indications at a Glance

CMS HPV Screening Billing Guidelines and Action Items 2026

This policy review went into effect January 9, 2026. If your billing team hasn't reviewed your cervical cancer screening billing workflows since July 2015 — when this NCD originally became effective — now is the time.

If your revenue cycle team handles high volume of OB/GYN or preventive care claims for Medicare patients, a targeted audit of the last 12 months of HPV co-test claims is worth doing before March 2026. Pull denials, check the denial reason codes, and trace them back to these four criteria. You'll likely find patterns.

CPT, HCPCS, and ICD-10 Codes for Cervical Cancer Screening Under NCD 365

A Note on Codes Under This Policy

NCD 365 as published does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for older NCDs — the code-level detail is often handled through claims processing instructions rather than the NCD document itself.

For billing purposes, reference CMS Transmittal 3460 (Medicare Claims Processing), which accompanies this NCD. That transmittal contains the applicable procedure codes and billing instructions your team needs for claim submission.

Do not use codes sourced from a third party as a substitute for the transmittal. Pull the codes directly from Transmittal 3460 or confirm them through your MAC's claims processing guidance.

Because this policy does not list specific codes, confirm current applicable codes with your compliance officer or billing consultant before the next claim submission cycle. Using outdated or incorrect codes on Medicare preventive screening claims is a straight line to denial.